Vor Bio to Participate in the Stifel 2024 Healthcare Conference

11/12/24 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VOR alert in real time by email

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host 1x1 investor meetings at the Stifel 2024 Healthcare Conference.

Stifel 2024 Healthcare Conference

Fireside Chat: Monday, November 18, 2024 at 2:25 pm ET

Location: New York, NY

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors

Sarah Spencer

+1 857-242-6076

[email protected]

Get the next $VOR alert in real time by email

Date	Price Target	Rating	Analyst
7/26/2022	$18.00	Outperform	Wedbush
4/27/2022	$6.00	Neutral	Goldman
12/17/2021	$26.00	Buy	HC Wainwright & Co.
12/3/2021	$38.00	Outperform	Robert W. Baird
12/3/2021	$38.00	Outperform	Baird
12/2/2021	$30.00	Outperform	Oppenheimer
10/19/2021	$40.00	Market Outperform	JMP Securities

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $VOR

$VOR SEC Filings

SEC Form 10-Q filed by Vor Biopharma Inc.

Vor Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure

Vor Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure

$VOR Press Releases

Fastest customizable press release news feed in the world

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

$VOR Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

$VOR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF SCIENTIFIC OFFICER Chakraborty Tirtha covered exercise/tax liability with 875 shares, decreasing direct ownership by 0.51% to 169,935 units (SEC Form 4)

CHIEF MEDICAL OFFICER Attar Eyal C. covered exercise/tax liability with 999 shares, decreasing direct ownership by 1% to 91,773 units (SEC Form 4)

Vice President of Finance Quinlan Amy covered exercise/tax liability with 206 shares, decreasing direct ownership by 0.41% to 50,312 units (SEC Form 4)

$VOR Market Insights

Live Market Insights

JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target

Oppenheimer Reiterates Outperform on Vor Biopharma, Lowers Price Target to $10

Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target

$VOR Financials

Live finance-specific insights

$VOR Leadership Updates

Live Leadership Updates

$VOR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

PureTech Health plc – Half-Year Report

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

Wedbush initiated coverage on Vor Biopharma with a new price target

Goldman initiated coverage on Vor Biopharma with a new price target

HC Wainwright & Co. initiated coverage on Vor Biopharma with a new price target

Recent Analyst Ratings for
$VOR

$VOR
SEC Filings

$VOR
Press Releases

$VOR
Large Ownership Changes

$VOR
Insider Trading

$VOR
Market Insights

$VOR
Financials

$VOR
Leadership Updates

$VOR
Analyst Ratings